FHD 286
Alternative Names: FHD-286Latest Information Update: 23 Dec 2024
At a glance
- Originator Foghorn Therapeutics
 - Class Amides; Amines; Antineoplastics; Morpholines; Pyridines; Pyrroles; Small molecules; Thiazoles
 - Mechanism of Action SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 - Available For Licensing Yes
 
Highest Development Phases
- Suspended Acute myeloid leukaemia; Myelodysplastic syndromes
 - Discontinued Non-small cell lung cancer; Uveal melanoma
 
Most Recent Events
- 23 Dec 2024 Discontinued - Preclinical for Non-small cell lung cancer in USA (PO)
 - 23 Dec 2024 Suspended - Phase-I for Acute myeloid leukaemia (Combination therapy, In adolescents, In the elderly, Second-line therapy or greater, In adults) in USA (PO)
 - 23 Dec 2024 Suspended - Phase-I for Myelodysplastic syndromes (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)